AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Acidic leucine-rich nuclear phosphoprotein 32 family member B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q92688

UPID:

AN32B_HUMAN

Alternative names:

Acidic protein rich in leucines; Putative HLA-DR-associated protein I-2; Silver-stainable protein SSP29

Alternative UPACC:

Q92688; B2R9C7; O00655; P78458; P78459

Background:

Acidic leucine-rich nuclear phosphoprotein 32 family member B, also known as Acidic protein rich in leucines, Putative HLA-DR-associated protein I-2, and Silver-stainable protein SSP29, plays a pivotal role in cell biology. It is involved in cell proliferation, apoptosis, cell cycle progression, and transcription regulation. This protein also exhibits histone chaperone properties, influencing the transcription of specific genes and is crucial in the nucleocytoplasmic transport of specific mRNAs. Additionally, it has a significant role in adaptive immune responses and mRNA expression.

Therapeutic significance:

Understanding the role of Acidic leucine-rich nuclear phosphoprotein 32 family member B could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.